Author

Boivin G

CHU de Qu

Biography

Dr. Guy Boivin is a professor in the Department of Microbiology-Immunology and Infectious Diseases of the Faculty of Medicine at Laval University. He holds the Canada Research Chair in Emerging Viruses and Antiviral Resistance, as well as a “Foundation” grant from the Canadian Institutes of Health Research (CIHR). He is also co-principal investigator of major grants, such as the FPQIS ($ 12M), for the development of new generation influenza vaccine in the elderly. Dr. Boivin is the author or co-author of 300 scientific publications and 350 presentations at various international conferences and symposia. 
Title
Cited by
Year
Viral interference between respiratory viruses
J Piret, G BoivinEmerging Infectious Diseases 28 (2), 273, 2022202
66
2022
Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2
J Prévost, J Richard, R Gasser, S Ding, C Fage, SP Anand, D Adam, ...Journal of Biological Chemistry 297 (4), 2021202
33
2021
Seroprevalence of SARS-CoV-2 antibodies among children in school and day care in Montreal, Canada
K Zinszer, B McKinnon, N Bourque, L Pierce, A Saucier, A Otis, I Cheriet, ...JAMA network open 4 (11), e2135975-e2135975, 2021202
24
2021
Influenza A (H1N1) pdm09 virus but not respiratory syncytial virus interferes with SARS-CoV-2 replication during sequential infections in human nasal epithelial cells
C Fage, M Hénaut, J Carbonneau, J Piret, G BoivinViruses 14 (2), 395, 2022202
21
2022
Microglia are involved in phagocytosis and extracellular digestion during Zika virus encephalitis in young adult immunodeficient mice
W Enlow, M Bordeleau, J Piret, FG Ibáñez, O Uyar, MC Venable, ...Journal of Neuroinflammation 18 (1), 1-24, 2021202
16
2021
Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study
Y Longtin, H Charest, C Quach, P Savard, M Baz, G Boivin, J Farfard, ...Infection Control & Hospital Epidemiology 43 (1), 102-104, 2022202
14
2022
Inhibition of the 3CL protease and SARS-CoV-2 replication by dalcetrapib
EJ Niesor, G Boivin, E Rhéaume, R Shi, V Lavoie, N Goyette, ME Picard, ...ACS omega 6 (25), 16584-16591, 2021202
14
2021
In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance
L Checkmahomed, J Carbonneau, V Du Pont, NC Riola, JK Perry, J Li, ...Antimicrobial Agents and Chemotherapy 66 (7), e00198-22, 2022202
12
2022
Single-cell transcriptomics of the ventral posterolateral nucleus-enriched thalamic regions from HSV-1-infected mice reveal a novel microglia/microglia-like transcriptional …
O Uyar, JM Dominguez, M Bordeleau, L Lapeyre, FG Ibáñez, L Vallières, ...Journal of Neuroinflammation 1 (1), 81, 2022202
9
2022
Seroprevalence of anti-SARS-CoV-2 antibodies among school and daycare children and personnel: protocol for a cohort study in Montreal, Canada
K Zinszer, B McKinnon, N Bourque, M Zahreddine, K Charland, ...BMJ open 11 (7), e053245, 2021202
8
2021
Ozone inactivation of airborne influenza and lack of resistance of respiratory syncytial virus to aerosolization and sampling processes
ME Dubuis, É Racine, JM Vyskocil, N Turgeon, C Tremblay, E Mukawera, ...Plos one 16 (7), e0253022, 2021202
8
2021
The REinfection in COVID‐19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers
É Racine, G Boivin, Y Longtin, D McCormack, H Decaluwe, P Savard, ...Influenza and Other Respiratory Viruses 16 (5), 916-925, 2022202
8
2022
Impact of amino acid substitutions in region II and helix K of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on resistance to foscarnet
K Zarrouk, X Zhu, VD Pham, N Goyette, J Piret, R Shi, G BoivinAntimicrobial Agents and Chemotherapy 6 (7), 10.1128/aac. 00390-21, 2021202
5
2021
A novel bioluminescent herpes simplex virus 1 for in vivo monitoring of herpes simplex encephalitis
O Uyar, PL Plante, J Piret, MC Venable, J Carbonneau, J Corbeil, ...Scientific Reports 11 (1), 18688, 2021202
4
2021
Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19
JC Tardif, M Cossette, MC Guertin, N Bouabdallaoui, MP Dubé, G Boivin, ...International Journal of Infectious Diseases 116, 387-390, 2022202
4
2022
Impact of temperature on the affinity of SARS-CoV-2 Spike for ACE2
J Prévost, J Richard, R Gasser, S Ding, C Fage, SP Anand, D Adam, ...bioRxiv, 2021.07. 09.51812, 2021202
4
2021
Avian Cell Line DuckCelt®-T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac®
C Chupin, A Pizzorno, A Traversier, P Brun, D Ogonczyk-Makowska, ...Vaccines 9 (10), 1190, 2021202
3
2021
Duration of isolation and contagiousness in coronavirus disease 2019 (COVID-19) patients receiving tocilizumab and dexamethasone: A case series
F Côté, G Boivin, V Loungnarath, A Ruest, J Bestman-Smith, ...Infection Control & Hospital Epidemiology 44 (4), 655-658, 20220
3
2023
Replication and transmission of an influenza A (H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs.
Replication and transmission of an influenza A (HN2) virus harboring the polymerase acidic I8T substitution, in guinea pigs.Z Mhamdi, J Carbonneau, MC Venable, M Baz, Y Abed, G BoivinJournal of General Virology 102 (10), 001659, 2021202
3
2021
Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended …
JJ LeBlanc, M ElSherif, L Ye, D MacKinnon-Cameron, A Ambrose, ...Vaccine 40 (18), 265-2646, 2022202
3
2022

Referred From: https://scholar.google.com/citations?user=7Qu14FcAAAAJ&hl=en

Cited by
Citations 26205
h-index 90
i10-index 302
Recommended Journals
Open Access Journals